Introduction
The prevalence of smoking among persons diagnosed with cancer is similar to the general population (Cox, Africano, Tercyak, & Taylor, 2003; Emmons et al., 2002; Ramaswamy, Toll, Chagpar, & Judson, 2016; Shoemaker, White, Hawkins, & Hayes, 2016; Tyc, 2005; . Many people with cancer continue to use cigarettes (Gritz, 2005; Klosky et al., 2007; Mackenbach, 2001; Mariotto, 2007) despite evidence of their negative effects on cancer treatment and other outcomes (Blum, 1997; Browman et al., 1993; Day, 1994; Des Rochers, Dische, & Saunders, 1992; Do et al., 2003; Gan et al., 2013; Khuri et al., 2006; Mason et al., 2009; Richardson, 1993; Shiels et al., 2014; Wynder, 1977) . Smoking cessation treatments can be effective among this population (Fiore et al., 2008; Kawahara et al., 1998; Tucker, 1997) .
Several evidence-based cessation treatments are available to assist smokers (Gritz et al., 2006; Siu, 2015) .
Approximately 250,000 cancer patients are treated at National Cancer Institute (NCI)-Designated Cancer Centers (NDCCs) or directly affiliated hospitals annually (National Cancer Institute, 2017b) . However, there is minimal research on tobacco treatment services offered at these facilities, and it is an area that requires further study (Singhi et al., 2015) . One available study (Goldstein, Ripley-Moffitt, Pathman, & Patsakham, 2013) reported that about half of NDCCs offered tobacco treatment services, and one-quarter had a program to refer patients (in addition to the services offered). Health People 2020 identified increasing tobacco screening efforts and tobacco cessation counselling in hospital ambulatory care settings as means to decrease tobacco use (Office of Disease Prevention and Health Promotion, 2017) . In this study, we examined treatment/cessation programs administered by hospitals providing oncology services and provided a descriptive analysis of the number of tobacco cessation programs available for patients at these facilities.
Methods
We examined 2008-2015 American Hospital Association (AHA) survey (American Hospital Association, 2017b) data collected from over 6,400 U.S hospitals. It is the largest annual survey of U.S. hospitals and collects information on hospital demographics, organisational structure, service types and utilisation, and business arrangements with physicians. Survey participants are not required to be members or registered with the AHA. Nonregistered hospitals are identified through state hospital associations, the Centers for Medicare and Medicaid Services, and other national organisations and government entities. The overall annual response rate is approximately 80% (American Hospital Association, 2017b). Unusual changes in data from one year to next are validated through contact with the hospital, and historic trends are examined for inconsistencies. Hospitals' data that was imputed (due to non-response) were excluded from this study. Survey responses are supplemented by data drawn from AHA registration database, the U.S. Census Bureau, hospital accrediting bodies, and other organisations. Hospitals completed the survey annually for the preceding operational year, and as such hospitals that completed the survey each year are included in multiple years of data when examined over time (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) . We decided to include all completed surveys for trend analyses to get a more accurate representation of services offered in each given operational year examined. However, only the most recent year of the data was included to summarise facility characteristics for NDCCs and HPOs.
Measures
We examined tobacco treatment/cessation programs among hospitals providing oncology services. All NDCCs and directly affiliated hospitals providing patient care were identified by designation year (National Cancer Institute, 2017b) . NDCC Basic Laboratories were excluded. Hospitals were grouped into two mutually exclusive categories: (1) NDCCs and directly affiliated facilities and (2) hospitals that reported providing oncology services owned by their hospital or its subsidiary (HPOs). Hospitals not meeting either of these two definitions were excluded. Hospitals were asked how tobacco treatment/cessation services are provided, specifying one or more: 'Owned or provided by my hospital or its subsidiary' , 'Provided by my Health System (in my local community)' , 'Provided through a formal contractual arrangement or joint venture with another provider not in my system (in my local community)' , or 'Do not provide' . Descriptions and definitions of survey items have been previously published (American Hospital Association, 2017a).
Statistical Analysis
Facility characteristics were stratified by group (NDCCs, HPOs). We analysed the data by NCI designation (Cancer Center, Comprehensive Cancer Center), hospital authority operations [Government (Federal, nonFederal) , non-Government (not-for-profit), or Investorowned (for profit)], capacity, utilisation, and staffing. Chi-square and Kruskal-Wallis tests were used to assess significant differences between groups. A test for trend was calculated to assess whether tobacco treatment/cessation program services increased significantly from 2008 to 2015. SAS (SAS Institute, Cary, NC) Enterprise Guide version 7.11 was used for all analyses. (Table 1) .
Results

From
The hospital authority for policy for NDCCs was significantly more likely to be Federal or non-Federal Government (98.8%), compared to HPOs (86.0%) (p < 0.001). NDCCs reported significantly more capacity, annual utilisation, and staffing compared with HPOs as reported for all hospital services. The mean number of total licensed beds reported by NDCCs (571) was more than double reported by HPOs (277) (p < 0.001). The mean number of total facility personnel reported annually by NDCCs (5,553) was more than triple of that reported by HPOs (1,490) (p < 0.001). Correspondingly, utilisation (mean number of admissions, inpatient days, and outpatient visits) reported by NDCCs was more than double reported by HPOs (p < 0.001).
NDCCs reported a significantly higher percentage of any tobacco treatment/cessation programs owned by the hospital or its subsidiary or provided in the local community (87.6-95.9%) than HPOs (75.1-80.3%) ( Table 2 ). The majority of cessation programs in both NDCCs and HPOs were owned by the hospital or its subsidiary (82.4% and 69.7% in 2015, respectively). Overall, tobacco treatment/cessation programs reported owned by the hospital or its subsidiary, the health system, or other contractual mechanism increased for both NDCCs and HPOs from 2008 to 2015.
Discussion
This is the first study to our knowledge to examine tobacco treatment/cessation programs administered across U.S. hospitals providing oncology services, including both NDCCs and HPOs. The annual percentage of tobacco treatment/cessation programs provided was While the majority of the tobacco treatment/cessation programs were owned or provided by their hospital or its subsidiary, a smaller percentage were provided by their health systems in the local community. This is somewhat consistent with a previous study, where NDCCs reported the majority of tobacco use treatment programs being owned by their centres (59%), and a lower percentage being external tobacco use treatment services in their health care system (21%) (Goldstein et al., 2013) . The higher reported number of total hospital staffing may further support the ability of NDCCs to provide tobacco treatment/cessation programs by the hospital as opposed to referring patients to an external, in-network resource in the local community. While the proportion of NDCCs with cessation programs and the increasing trend reported here are encouraging, a majority of cancer centers have stated that they do not perceive tobacco cessation treatment delivery as a core health care service (Goldstein et al., 2013) . Therefore, the high percentage of programs available in hospitals may not reflect the actual use of these programs. One study of online resources suggested that detailed risks of tobacco use and cessation program contact information may be lacking for cancer patients (Singhi et al., 2015) . Additionally, some have reported that smokers may be motivated to quit smoking following a cancer diagnosis, (Nayan, Gupta, Strychowsky, & Sommer, 2013; Westmaas et al., 2015) , but health professionals often miss opportunities to recommend smoking cessation (Earle & Neville, 2004; Sabatino, 2007; Weaver et al., 2012) .
NCI Comprehensive Cancer Centers are required to develop effective cancer prevention and education approaches; however, the types of tobacco treatment/cessation programs offered and how they are administered have yet to be evaluated. NCI recently released short-and long-term initiative funding to enhance NDCC capacity to address tobacco cessation with cancer patients and implement sustainable tobacco cessation treatment programs (National Cancer Institute, 2017a) . Further examination of the adoption, referral, use and barriers to use, and efficacy of cessation methods in these hospitals would inform efforts to reduce smoking among cancer survivors in hospitals and non-hospital settings. NDCCs and HPOs may also consider voluntary implementation of the Joint Commission's hospital cessation measures (The Joint Commission, 2012). The Centers for Disease Control and Prevention's (CDC) National Comprehensive Cancer Control Program (NCCCP) supports increasing knowledge and availability of evidence-based 
Limitations
The study is subject to several limitations: AHA survey data are self-reported by hospitals each year; individual hospital measures reported are not completely validated; and the data are based on a sample of U.S. hospitals. However, these data are corrected for unusual changes and serve as the primary hospital-related reference for several government agencies (American Hospital Association, 2017b). AHA data do not provide details on the type, extent, or specifics of any tobacco treatment/cessation programs offered, used, or referral follow-up. Results aggregated over time include surveys from the same hospital in different years, but accurately reflect current services provided by each hospital during the year the survey was completed.
Conclusions
More than 80% of hospitals providing oncology services report providing tobacco cessation programs with higher percentages reported in NDCCs. As hospitals implement more smoking cessation programs, partnerships between hospitals and cancer coalitions could help to bring tobacco cessation activities to the communities that they both serve and link discharged patients to these cessation resources so that they can continue quit attempts that they initialised while hospitalised.
